Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.96 EUR
Change Today -0.01 / -1.03%
Volume 1.3K
EZBG On Other Exchanges
EN Brussels
As of 6:01 AM 10/13/15 All times are local (Market data is delayed by at least 15 minutes).

eckert-ziegler bebig (EZBG) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/16/14 - €1.85
52 Week Low
10/2/15 - €0.96
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ECKERT-ZIEGLER BEBIG (EZBG)

Related News

No related news articles were found.

eckert-ziegler bebig (EZBG) Related Businessweek News

No Related Businessweek News Found

eckert-ziegler bebig (EZBG) Details

Eckert & Ziegler BEBIG s.a., through its subsidiaries, develops, manufactures, and sells radiation equipment and related products and components based on isotope technology. The company offers IsoSeed, a seed implant for the treatment of prostate cancer; IsoCord, a seed chain with up to 75 seeds in a magazine that provides optimal radiation protection; IsoStrand, which consists of 10 IsoSeed spaced 1 cm apart; Permanent Seed Implant Dosimetry, a software for prostate brachytherapy; needles for LDR brachytherapy; and AnchorSeed, a loose seed with a bioabsorbable encapsulation. It also provides SagiNova and MultiSource HDR (high dose rate) afterloader systems for the HDR brachytherapy applications; GyneSource, a five channel HDR afterloader developed for gynaecological brachytherapy treatments; HDR applicators for intraluminal, interstitial, intracavitary, and intraoperative treatments, as well as surface mold treatments; SagiPlan and HDRplus software products, which deliver HDR treatment plan; and Cobalt-60 for various HDR brachytherapy treatments. In addition, the company offers products for the temporary brachytherapy of eye cancers, including Ru-106 Eye Applicators, a brachytherapy source that is used in the treatment of uveal melanoma, retinoblastoma, and melanoma of the iris, as well as for other applications; and I-125 Ophthalmic Seeds for use in COMS Eye Applicators to treat intraocular tumors, such as uveal melanoma or retinoblastoma. Further, it provides radiotherapy accessories. The company offers its products to oncologists, radiologists, urologists, and medical physicists through a network of distributors and agents worldwide. The company was formerly known as International Brachytherapy s.a. and changed its name to Eckert & Ziegler BEBIG S.A. in June 2011. Eckert & Ziegler BEBIG s.a. was founded in 1996 and is based in Seneffe, Belgium. Eckert & Ziegler BEBIG s.a. is a subsidiary of Eckert & Ziegler AG.

200 Employees
Last Reported Date: 08/4/15
Founded in 1996

eckert-ziegler bebig (EZBG) Top Compensated Officers

Managing Director, Executive Director and Mem...
Total Annual Compensation: €221.5K
Compensation as of Fiscal Year 2014.

eckert-ziegler bebig (EZBG) Key Developments

Eckert & Ziegler BEBIG Names Dr. Harald Hasselmann as New Commercial Managing Director for Sales and Finances

As part of the restructuring measures Eckert & Ziegler BEBIG appointed business administration expert Dr. Harald Hasselmann (aged 48) as the new commercial managing director for sales and finances. With effect from October 1, 2015 he will be a member of the management team and head the company together with Dr. Edgar Loffler, a medical physicist, who is responsible for the irradiation equipment manufacturer's technical operations. Abel Luzuriaga, who has been managing director for sales and marketing at Eckert & Ziegler BEBIG since 2012, is leaving the company of his own accord. Harald Hasselmann, born in Hamburg, has gained extensive experience at various international pharmaceutical companies. He was head of controlling for Europe at Bayer Pharma, managing director at Schering's Hungarian subsidiary and director of the Berlin-based biotech company metaGen. He has held various positions in large and medium-sized healthcare companies and has an excellent track record in sales, controlling and implementing restructuring measures.

Eckert & Ziegler Bebig S.A. Reports Unaudited Consolidated Earnings Results for the Six Months ended June 30, 2015

Eckert & Ziegler BEBIG S.A. reported unaudited consolidated earnings results for the six months of 2015. For the period, the company reported sales of €14,761,000 against €13,903,000 a year ago. Operating result negative was €1,725,000 against €958,000 a year ago. Loss before interest and taxes was €1,725,000 against €958,000 a year ago. Loss before tax was €1,908,000 against €1,251,000 a year ago. Net loss was €2,661,000 against €967,000 a year ago. Net loss per share was €0.15 against €0.06 per share a year ago. Cash inflow generated from operating activities was €177,000 against cash outflow generated from operating activities of €576,000 a year ago.

Eckert & Ziegler BEBIG Announces Earnings Results for the Year 2014

Eckert & Ziegler BEBIG announced earnings results for the year 2014. For the year, the company reported sales of EUR 28.8 million compared to EUR 27.8 million in 2013. Loss per share was EUR 0.17.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EZBG:BB €0.96 EUR -0.01

EZBG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $189.13 USD +2.42
Elekta AB kr62.25 SEK -1.10
View Industry Companies

Industry Analysis


Industry Average

Valuation EZBG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.6x
Price/Book 0.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ECKERT-ZIEGLER BEBIG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at